CTTI is excited to introduce its Mobile Clinical Trials (MCT) Program, which will identify and address challenges to the use of mobile technologies to facilitate clinical trials for regulatory submissions. These technologies have the potential to increase the quality and efficiency of clinical trials by allowing remote participation and monitoring, creating opportunities to develop novel endpoints, and streamlining data collection.

The integration of mobile technologies into clinical trials is in the early phases. Through the MCT Program, CTTI will help create a pathway to drive this promising transformation.

CTTI’s MCT Program includes four projects addressing specific challenges. Within each of these areas, CTTI’s multi-stakeholder teams have begun gathering evidence to develop tools and best practices that can be deployed throughout the clinical trials enterprise to promote widespread integration of mobile technologies.

 

Learn more about the CTTI MCT projects:

1. Legal and Regulatory Issues
2. Novel Endpoints
3. Stakeholder Perceptions
4. Use of Mobile Devices

CTTI will present on this new initiative at the Mobile in Clinical Trials Conference on Monday, September 19, 2016.

CTTI’s Mobile Clinical Trials (MCT) Program focuses on integrating new mobile technologies in the design and conduct of clinical trials. Although medical research steadily progresses, the clinical trial enterprise can be slow to adopt new approaches and tools. As noted by Janet Woodcock in a recent article published by The Guardian, both pharmaceutical companies and regulators desire more innovation in the clinical trial setting. Aligned with this goal, the article recognized CTTI efforts to help increase innovation through initiating the MCT program. Dr. Martin Landray, a MCT Program leader and medical expert, was also quoted in the article, acknowledging that many currently used tests or metrics are outdated and do not provide the best information to guide patient treatment. He points out that wearable technology can provide more comprehensive data on a patient’s activities and health measurements. Additionally, according to The Guardian article, Landray

“estimates that in some cases, shifting to a mobile-based trial may reduce costs by 10-fold. This cost cutting, coupled with the fact that mobile trials’ recruitment efforts are not limited by geography, has the potential to advance our scientific understanding of rare diseases.”

CTTI is committed to helping the clinical trial enterprise explore the benefits offered by technological advancements with remote capabilities. The MCT Program seeks to address important issues related to the successful integration of mobile technologies in clinical trial conduct, including receptivity within the current legal/regulatory frameworks, stakeholder perceptions regarding risks and benefits of its use, and technical aspects of practical application.